CAR-T biotech Kelonia rebounds from cash crises to a $3 billion sale, while drugmakers explore Prescribery partnership
The latest episode of STAT's "The Readout LOUD" podcast focuses on a dramatic turnaround at a CAR‑T biotech that faced near‑bankruptcy three times before being bought for more than $3 billion.
The company, Kelonia Therapeutics, struggled with cash flow repeatedly, yet managed to secure a high‑value acquisition that highlights how investors can revive distressed assets.
The discussion also turns to how large drugmakers are partnering with a telehealth firm called Prescribery to generate more prescription scripts, illustrating a new commercial tactic in the industry.
Venture capitalist Bryan Roberts joins hosts Allison DeAngelis, Elaine Chen and Adam Feuerstein to unpack the deal dynamics and the broader implications for biotech financing and drug‑company strategies.
This writeup was produced by pharmadog from original reporting by STAT.
Original headline: “A CAR-T biotech’s dramatic turnaround, and drugmakers’ tactics to drive more scripts”
read at STAT ↗
comments(0)
5-min edit window · permanent after that